Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States

被引:7
作者
Straka, RJ
Hansen, SR
Benson, SR
Walker, PF
机构
[1] ST PAUL RAMSEY MED CTR, SECT CLIN PHARM, ST PAUL, MN 55101 USA
[2] ST PAUL RAMSEY MED CTR, RAMSEY CLIN, INT CLIN, DEPT INTERNAL MED, ST PAUL, MN 55101 USA
关键词
D O I
10.1002/j.1552-4604.1996.tb04244.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacogenetics can be an important determinant of pharmacologic response. To learn more about interpopulation differences in drug metabolism between ethnically diverse populations of subjects cared for by an International Clinic, a study was conducted to describe the prevalence of fast or slow acetylators of N-acetyl transferase (NAT2) in a population of Hmong residing in Minnesota. Ninety-eight healthy Hmong refugees from Laos volunteered to take caffeine as an oral probe drug to establish acetylator phenotype. Participants were classified as either rapid or slow acerylators based on the urinary molar ratio of select metabolites of caffeine. Assignment of phenotype was based on results from analysis of urine collected subsequent to ingestion of caffeine, The ratio of 5-acetylamino-6-formylamino-3-methyluracil (AFMU) to the combined products of the 7-demethylation pathway of paraxanthine [AFMU, 1-methylxanthine (1X), and 1-methylurate (1U)] formed the basis for this determination. A probit plot of the data collected in our subjects qualified a metabolic ratio of 0.34 as an acceptable cut point for phenotype assignment, Participants with an AFMU/(AFMU + 1X + 1U) ratio of <0.34 were classified as slow acetylators and all others as rapid acetylators. Analysis of the data su distribution with an excess (74.5%) of slow acetylators in the population, The predominance of slow acetylators found in the Hmong contrast with the prevalence of slow acetylators seen in other ethnic groups, These findings may have important clinical implications given the large number of Hmong treated each year in our International Clinic and the increasing use of medications metabolized by NAT2 in this population.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 36 条
[1]  
ARMSTRONG AR, 1960, AM REV RESPIR DIS, V81, P588
[2]  
CDC, 1994, MMWR-MORBID MORTAL W, V43, P361
[3]   FURTHER-STUDIES OF SULFASALAZINE METABOLISM IN TREATMENT OF ULCERATIVE-COLITIS [J].
COWAN, GO ;
DAS, KM ;
EASTWOOD, MA .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 2 (6094) :1057-1059
[4]   ADVERSE REACTIONS DURING SALICYLAZOSULFAPYRIDINE THERAPY AND RELATION WITH DRUG-METABOLISM AND ACETYLATOR PHENOTYPE [J].
DAS, KM ;
EASTWOOD, MA ;
MCMANUS, JPA ;
SIRCUS, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (10) :491-495
[5]   ANTINUCLEAR ANTIBODIES DURING PROCAINAMIDE TREATMENT AND DRUG ACETYLATION [J].
DAVIES, DM ;
BEEDIE, MA ;
RAWLINS, MD .
BRITISH MEDICAL JOURNAL, 1975, 3 (5985) :682-684
[6]  
DEVADATTA S, 1960, Bull World Health Organ, V23, P587
[7]  
EVANS DAP, 1964, J LAB CLIN MED, V63, P394
[8]   GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].
EVANS, DAP ;
MANLEY, KA ;
MCKUSICK, VA .
BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491
[9]  
EVANS DAP, 1993, GENETIC FACTORS DRUG
[10]   VARIABILITY IN CAFFEINE METABOLISM [J].
GRANT, DM ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (05) :591-602